Ainos Inc

Ainos, Inc. is a healthcare company engaged in the discovery and development of pharmaceutical and biotech products. It operates through the following divisions: Pharmaceutical, Medical, and Consumer. The company was founded in June 1984 and is headquartered in San Diego, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded on June 26, 1984 and is headquartered in San Diego, CA.

The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform development From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.

CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its participation in the Webull Corporate Connect Service (CCS). This initiative aims to further expand the Company's investor outreach and enhance transparency with its growing shareholder base.

Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement

SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research has issued a report highlighting Ainos' strategic partnership with Taiwan Tanabe Seiyaku for manufacturing and marketing VELDONA®, a novel therapeutic candidate for primary Sjögren's syndrome, in Taiwan. The report underscores the significance of Ainos' efforts to out-license VELDONA®, starting with this key regional partnership, and sets the stage for future global expansion.

Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing

San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical development and manufacturing expertise to the partnership.

Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug

Taiwan regulatory approval for the trial expected in Q1 2025 Remains committed to a capital-efficient business strategy SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report on the Company's obtainment of Institutional Review Board ("IRB") approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the VELDONA® clinical study for primary Sjogren's syndrome, along with 3Q24 results and multiple other developments. The report said an approval from Taiwan's Food and Drug Administration (TFDA) for the study is expected in next quarter, with the trial set to start around April 2025 and completion in December 2026.

Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

IRB approval on track as scheduled Next step is obtaining all regulatory approvals, followed by site initiation visit VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has received Institutional Review Board ("IRB") approval from Shuang Ho Hospital, affiliated with Taipei Medical University (IRB Approval No.: TMU-JIRB No.

Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics, today announced it has filed complaints with NASDAQ MarketWatch and the U.S. Securities and Exchange Commission (SEC), due to concerns about unusual trading activity in its common stock, specifically large-volume sell orders. Ainos suspects that these trading activities may involve regulatory violations and urges the regulators to investigate thoroughly to uphold market fairness and protect stockholder interests.

Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

Secured multi-regional patent assets, strengthening Ainos' AI Nose technology. Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.

Ainos Reports Third Quarter 2024 Financial Results

Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbon Nano Technology Corporation ("TCNT"). These patents encompass innovations in AI Nose gas sensing technology and extend Ainos' technological capabilities with a groundbreaking nitrogen-oxygen separation technology targeting medical applications.

Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets

Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome Burgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / October 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, shared promising clinical progress of VELDONA® and its growth opportunities alongside upcoming milestones in the Water Tower Research ("WTR") Small-Cap Spotlight podcast, signaling strong potential for both human and animal health markets. WTR has published a report recapping highlights from the podcast.

Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast

Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots VELDONA® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments SAN DIEGO, CA / ACCESSWIRE / October 7, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it continues to push the boundaries of global smart healthcare and immunotherapy innovation. With its AI Nose and VELDONA® low-dose oral interferon technologies, Ainos is not only spearheading advancements in medical technology but also demonstrating significant potential for industrial safety and automation applications.

Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA) SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients. This trial will evaluate VELDONA®, Ainos' low-dose oral interferon formulation, which has received orphan drug designation from the U.S. Food and Drug Administration ("FDA"), as a potential treatment for HIV-related oral warts.

Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

Sjogren's Syndrome is a rare autoimmune disease with limited treatment options Prior U.S. Phase 3 data demonstrated benefits SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's upcoming clinical study for VELDONA® in treating primary Sjogren's syndrome, targeted to begin in December 2024 in Taiwan. The report emphasizes Ainos' capital-efficient strategy in conducting clinical trials within Taiwan.

Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome

Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion Ainos aims to complete all regulatory approvals for the study in Q4 2024 SAN DIEGO, CA / ACCESSWIRE / September 23, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that it plans to conduct a Taiwan clinical study for very low-dose interferon alpha (VELDONA) on treating Sjögren's syndrome at Taipei Medical University-Shuang Ho Hospital. A total of eight clinical trials have been conducted in the U.S. by the Company to evaluate the use of VELDONA® for treating Sjögren's syndrome.

Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options

SAN DIEGO, CA / ACCESSWIRE / September 20, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has issued a note on the Company's upcoming clinical trial for VELDONA ® , a low-dose oral interferon-alpha formulation, in treating oral warts in HIV+ patients on antiretroviral therapy ("ART"). The report highlights Ainos' commitment to advancing cost-efficient clinical research alongside a single-site, double-blind study set to commence at the National Taiwan University Hospital ("NTUH") by November 2024.

Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA® Low-Dose Oral Interferon Formulation as a Potential Treatment for Oral Warts in HIV-Positive Patients SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that its plans to initiate a clinical study for very low-dose interferon alpha (VELDONA) on treating Human immunodeficiency virus (HIV)-related oral warts at the National Taiwan University Hospital. The study aims to evaluate the efficacy of VELDONA®, a low-dose oral interferon-alpha formulation, in treating oral warts in HIV-positive patients undergoing combination antiretroviral therapy.

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

This patent marks a major leap in Ainos' antiviral research, contributing to global efforts against coronavirus infections SAN DIEGO, CA / ACCESSWIRE / September 3, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that its groundbreaking VELDONA® formulation has been granted an invention patent in Taiwan and has filed for global patent protection under the Patent Cooperation Treaty (PCT). This patent represents a significant milestone in the treatment and prevention of coronavirus infections.

Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

Company invites shareholders and all interested parties to learn our journey for ultimately becoming AI's nose capable of digitizing smell. SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that it will be attending the H.C.

Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Embarking on a journey to ultimately becoming AI's nose capable of digitizing smell AI Nose journey begins in healthcare and is now expanding into smart factories SAN DIEGO, CA / ACCESSWIRE / August 26, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, is pleased to provide an update letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.

Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter

AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories AI Nose can be integrated into robotics systems in smart factories, serving as the digital nose of AI technology SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that its AI Nose has made a significant breakthrough in factory automation with 79% accuracy in detecting 761 samples across 22 different volatile organic compounds (VOCs). This is a remarkable technological advancement in industrial manufacturing safety and smart manufacturing.

Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Ainos (NASDAQ: AIMD ) stock is heading higher on Monday after the medical technologies development company secured new patent licenses. According to a press release from Ainos, the company has obtained exclusive licenses for 10 patents from Taiwan Carbon Nano Technology.

Why Is Ainos (AIMD) Stock Up 38% Today?

SAN DIEGO, CA / ACCESSWIRE / August 12, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that it will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") on Thursday, August 22, 2024 at 10:00 a.m. ET. Mr. Jack Lu, Ainos' Director of Corporate Development, will provide an overview of the Company's business model, strategic priorities, and innovative AI Nose technology platform.

Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024

Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devices All-stock licensing structure aligns the licensor's long-term interest with Ainos shareholders' SAN DIEGO, CA / ACCESSWIRE / August 9, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology ("TCNT"), the Company's affiliate and product co-developer. TCNT agreed to assign and grant exclusive, irrevocable, and perpetual licenses of 10 invention patents and patent applications related to gas sensors and medical devices in exchange for the Company's shares of common stock with a total value of approximately US$5.4 million.

Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing

Maintaining robust financial runway after the prepayment Reinforcing Ainos' commitment towards building shareholder value SAN DIEGO, CA / ACCESSWIRE / August 6, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced that the Company has prepaid its remaining convertible note financing (the "Note") with Lind Global Fund II LP, an institutional investment fund managed by The Lind Partners (together the "Investor"), through conversions of the Note by the Investor and payments by the Company, which aggregates at a total of approximately US$1.67 million. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and CEO of Ainos, commented, "We remain extremely appreciative of the financial support from The Lind Partners, which provided us the growth capital to execute our VELDONA and AI Nose development plans.

News for Ainos Inc Stock (AIMD)